Cargando…
710. In Vitro Activity and Performance of Available Susceptibility Testing Methods for Eravacycline Against Carbapenem-Resistant Enterobacteriaceae (CRE)
BACKGROUND: Eravacycline (ERV) is a recently-approved, fully synthetic fluorocycline agent that demonstrates broad in vitro activity against multidrug-resistant pathogens. We sought to compare the activity of ERV with minocycline (MIN) and tigecycline (TGC) against diverse CRE clinical isolates, and...
Autores principales: | Jones, Chelsea E, Kline, Ellen G, Nguyen, Minh-Hong, Clancy, Cornelius J, Shields, Ryan K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811212/ http://dx.doi.org/10.1093/ofid/ofz360.778 |
Ejemplares similares
-
2247. Real-world Experience with Meropenem–Vaborbactam (M/V) for Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections
por: Shields, Ryan K, et al.
Publicado: (2019) -
1378. Evaluation of the In vitro Activity of Meropenem-Vaborbactam Against Carbapenem-Resistant Enterobacteriaceae, Including Isolates Resistant to Ceftazidime–Avibactam
por: Wilson, William R, et al.
Publicado: (2018) -
2667. Does Ceftazidime–Avibactam (CAZ-AVI) Improve Short- and Long-Term Outcomes Among Solid-Organ Transplant (SOT) Recipients with Carbapenem-Resistant Enterobacteriaceae (CRE) Infections?
por: Sun, Jonathan, et al.
Publicado: (2019) -
524. Understanding the Treatment of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections in the United States (US): Insights from a Survey of Hospital-Based Pharmacists
por: Potoski, Brian, et al.
Publicado: (2019) -
Multicenter Clinical Evaluation of ETEST Eravacycline for Susceptibility Testing of Enterobacteriaceae and Enterococci
por: Blanchard, Laurine S., et al.
Publicado: (2023)